|Articles|April 22, 2019
Technology Matters: How the Pap Test Protects Your Patients
Advertisement
The Pap test reduces the incidence of cervical cancer and its precursors for women around the world but has limitations in sensitivity and accuracy.
Liquid-based cytology improves detection of dysplasia and cervical malignancy while producing fewer unsatisfactory or insufficient results. This supplement examines the science, development and clinical benefits of ThinPrep® - the first FDA-approved, liquid-based cytological testing method for women aged 30 and older.
Read this online supplement to learn more about the latest in developments in cervical cancer screening.
Newsletter
Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Phase 1 trial shows promise for triple-negative breast cancer vaccine
2
No evidence links menopause hormone therapy to dementia risk
3
Disrupted uterine scar healing may drive placenta accreta spectrum development
4
Opioid use in pregnancy raises maternal and infant risks
5







